BioMarin’s Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target

Analyst William Pickering of Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), boosting the price target to $95.00.

William Pickering has given his Buy rating due to a combination of factors including BioMarin Pharmaceutical’s strategic acquisition of Inozyme. This acquisition is seen as a strong fit with BioMarin’s existing business units and research and development capabilities, potentially enhancing their market position. The deal, valued at $270 million, is expected to close in the third quarter of 2025 and includes Inozyme’s promising drug candidate, INZ-701, which targets ENPP1 deficiency. BioMarin anticipates initial approval for this treatment in children by 2027, with an expansion into adults and adolescents in the early 2030s, aiming for peak sales of $400-600 million by the mid-2030s.
Furthermore, BioMarin has reaffirmed its operational guidance, indicating that the acquisition will not negatively impact their financial outlook for 2025. The company maintains a 40% operating margin guidance for 2026, demonstrating confidence in its ability to integrate Inozyme’s operations efficiently. These strategic moves, along with minor positive adjustments to estimates and an extension of forecasts, have led to an increased price target of $95 for BioMarin’s stock, reflecting a positive outlook on the company’s growth prospects.

Pickering covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Beam Therapeutics. According to TipRanks, Pickering has an average return of -9.2% and a 42.86% success rate on recommended stocks.

In another report released on May 16, TD Cowen also reiterated a Buy rating on the stock with a $120.00 price target.